Nicotinamide

Nicotinamide (niacinamide) is the amide form of vitamin B3 that serves as a precursor to NAD+ and NADP+, coenzymes critical for DNA repair, energy metabolism, and cellular signaling. Unlike nicotinic acid, it does not activate GPR109A receptors, so it delivers therapeutic effects without causing skin flushing.

Origin & History

Nicotinamide (niacinamide) is the amide form of vitamin B3, a water-soluble vitamin essential for cellular metabolism. It is produced synthetically or derived from natural sources like yeast, bacteria, or animal tissues through chemical amidation of nicotinic acid. Chemically belonging to the pyridine carboxamide class, it serves as a precursor to NAD+, a critical coenzyme in redox reactions.

Historical & Cultural Context

No historical traditional medicine use was documented in the research. Nicotinamide is a modern synthetic form of vitamin B3, studied primarily in contemporary clinical contexts rather than ethnobotanical systems. Its use emerged from 20th-century nutritional science and vitamin research.

Health Benefits

• Reduces non-melanoma skin cancers by 23% in high-risk patients (Strong evidence: Phase 3 RCT, n=386, PMID: 26488693)
• Decreases actinic keratoses by 11-20% over 12 months (Strong evidence: Phase 3 RCT, PMID: 26488693)
• Lowers squamous cell carcinoma risk by 30% (Moderate evidence: Phase 3 RCT, PMID: 26488693)
• Enhances DNA repair and reduces UV-induced immunosuppression (Mechanistic evidence from clinical trials)
• Supports cellular energy metabolism through NAD+ production (Preliminary evidence: related NAD+ precursor studies)

How It Works

Nicotinamide is converted intracellularly to NAD+ via the salvage pathway, where nicotinamide phosphoribosyltransferase (NAMPT) catalyzes its conversion to nicotinamide mononucleotide (NMN), which is subsequently adenylated by NMNAT enzymes. Elevated NAD+ activates PARP-1 and PARP-2, enzymes that repair UV-induced DNA strand breaks, and also fuels sirtuins (SIRT1–SIRT7), deacetylases that regulate inflammation and genomic stability. Additionally, nicotinamide inhibits poly-ADP-ribose polymerase overactivation that would otherwise deplete NAD+ stores during oxidative stress, preserving cellular energy reserves.

Scientific Research

The landmark ONTRAC Phase 3 RCT (PMID: 26488693) demonstrated nicotinamide's efficacy in 386 high-risk patients, showing 23% reduction in new non-melanoma skin cancers. A meta-analysis (PMID: 37994989) pooled 4 RCTs but found mixed results, with clearer benefits for squamous cell carcinoma prevention. A pilot study in kidney transplant recipients (PMID: 37838527) showed limited efficacy with tolerability issues at higher doses.

Clinical Summary

The strongest evidence comes from a Phase 3 RCT (n=386, PMID: 26488693) in high-risk patients, demonstrating that 500 mg twice-daily oral nicotinamide reduced new non-melanoma skin cancers by 23%, actinic keratoses by 11–20%, and squamous cell carcinoma incidence by approximately 30% over 12 months compared to placebo. These benefits disappeared within 6 months of discontinuation, indicating the effect requires sustained supplementation. Dermatological evidence is rated strong given the double-blind, placebo-controlled design and clinically meaningful effect sizes. Evidence for other proposed benefits — including glucose metabolism, inflammatory skin conditions, and osteoarthritis — is generally rated moderate to weak, drawn from smaller or shorter trials with less consistent outcomes.

Nutritional Profile

Nicotinamide (niacinamide) is the amide form of vitamin B3 (niacin), with a molecular weight of 122.12 g/mol. It is a water-soluble vitamin that serves as the precursor to nicotinamide adenine dinucleotide (NAD+) and nicotinamide adenine dinucleotide phosphate (NADP+), two critical coenzymes involved in over 400 enzymatic reactions. Standard supplemental doses range from 500 mg to 1500 mg/day (typically 500 mg twice or thrice daily for skin cancer chemoprevention). Oral bioavailability is high (~100%), rapidly absorbed in the small intestine, with peak plasma levels reached within 1-2 hours. Unlike nicotinic acid, nicotinamide does not cause flushing at therapeutic doses. It contains no macronutrients, fiber, or minerals—it is a pure bioactive compound. Hepatic metabolism converts nicotinamide to NAD+ via the salvage pathway enzyme nicotinamide phosphoribosyltransferase (NAMPT). Excess is methylated to N-methyl-nicotinamide and further oxidized metabolites excreted renally. Dietary sources include poultry (~12 mg/100g), tuna (~8.6 mg/100g), beef liver (~16 mg/100g), and fortified cereals, though chemoprevention doses far exceed dietary intake (~15-20 mg NE RDA).

Preparation & Dosage

Clinically studied doses use oral tablets or powder: 500 mg twice daily (1000 mg total) for skin cancer prevention, based on the ONTRAC trial. Some patients require dose reduction to 500 mg once daily due to gastrointestinal tolerability. Studies used pharmaceutical-grade nicotinamide without standardization beyond purity. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Nicotinamide pairs well with broad-spectrum sunscreen (SPF 50+), which provides additive photoprotection—nicotinamide enhances cellular DNA repair (boosting nucleotide excision repair by ~20-40%) while sunscreen blocks UV penetration, together reducing actinic keratoses more than either alone. Combining with zinc (30 mg/day as zinc picolinate) supports poly(ADP-ribose) polymerase (PARP) activity—a zinc-finger DNA repair enzyme that consumes NAD+—ensuring both the cofactor (NAD+ from nicotinamide) and the structural mineral (zinc) are available for optimal DNA damage response. Vitamin D3 (1000-2000 IU/day) complements nicotinamide's immunoprotective effects, as UV avoidance strategies often reduce endogenous vitamin D synthesis, and vitamin D itself has anti-proliferative effects on keratinocytes. Additionally, sulforaphane (from broccoli seed extract, ~30 mg/day) upregulates Nrf2-mediated antioxidant defenses and phase II detoxification enzymes, providing a complementary chemopreventive mechanism alongside nicotinamide's NAD+-dependent energy and repair pathways. Resveratrol (150-250 mg/day) may further synergize by activating sirtuins (SIRT1/SIRT3), NAD+-dependent deacetylases that regulate cellular stress responses, though nicotinamide itself is a weak sirtuin inhibitor at high concentrations, so moderate dosing of both is advisable.

Safety & Interactions

Nicotinamide is generally well tolerated at supplemental doses up to 1,500 mg/day, with nausea, headache, and mild gastrointestinal upset reported at higher doses; hepatotoxicity has been observed with chronic use above 3,000 mg/day. Unlike nicotinic acid, it does not cause prostaglandin-mediated flushing, making it preferable for patients who cannot tolerate that form. Clinically relevant drug interactions include potentiation of anticonvulsants (e.g., carbamazepine, valproate) and potential additive effects with insulin or sulfonylureas on glucose regulation. Nicotinamide is considered safe during pregnancy at dietary intake levels (RDA: 18 mg NE/day for pregnant women), though high-dose supplementation during pregnancy lacks robust safety data and should be avoided without medical supervision.